Abbott sued for patent infringement over infant probiotic
Evolve BioSystems and the University of California have jointly sued Abbott Laboratories for patent infringement over a soon-to-be-launched probiotic product.
FDA and DEA warn over sale of misbranded opioid drugs
The US Food and Drug Administration and Drug Enforcement Administration have issued joint warning letters to four online networks which allegedly sell unapproved and misbranded versions of medicines.
Taiwanese firm accuses Pacific Biosciences of infringing sequencing tech
Taiwan-based Personal Genomics Taiwan has taken gene-sequencing rival Pacific Biosciences to court in the US, over alleged patent infringement.
Drug-to-market cost falls to under $2bn in five years
Bringing a drug to market is costing companies under $2 billion for the first time in five years, according to a report from IP service provider Clarivate Analytics.
UK parliament report reveals threat to medical supplies post-Brexit
An independent parliamentary report has today, September 27, revealed that the UK’s health ministry remains unsure whether the country’s health service can fully withstand the impact of a no-deal Brexit next month.
Bayer and Boston hospitals collaborate on COPD lab
Bayer and two Boston hospitals have joined forces in a chronic lung disease research product, with the trio championing the ‘joint lab’ model as a blueprint for pharmaceutical research.
China awards generics contracts to lowest bidders
China’s drug pricing overhaul has seen the average cost of drugs drop by more than half, the country’s Joint Procurement Office announced this week.
Greensfelder appoints Missouri-based patent attorney
Greensfelder, Hemker & Gale has appointed Jared Manse to its St Louis office as an associate in the firm’s IP Practice Group.
UK Labour promises public generics company, compulsory drug licensing
Jeremy Corbyn, leader of the UK Labour Party, has pledged to create a publicly-owned drugs manufacturer and use compulsory licensing to sell generic, lower priced versions of drugs to the country’s National Health Service.
EU parliament challenges EPO on plant patentability
The European Parliament has said that the internal rules of the European Patent Office “must not undermine democratic political control of European patent law”.
